Next gen ACLY inhibitor therapy(Esperion Therapeutics)

N/A

Report date: 2024/02/05 15:01:11
NME

Base Information

Drug NameNext gen ACLY inhibitor therapy(Esperion Therapeutics)
Drug Alias NameATP-citrate lyase inhibitor therapy(Esperion Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-citrate synthase inhibitors
TargetsATP-citrate synthase
Therapy Area/IndicationsKidney DiseasesLiver DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEsperion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEsperion Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsKidney DiseasesLiver DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A